Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Nakame Y, Saitoh H, Negishi T, Yamada T, Kageyama Y, Kura N
Department of Urology, Saitama Medical Center, Saitama Medical School.
Hinyokika Kiyo. 1988 Dec;34(12):2225-32.
Aztreonam (AZT) (2 g daily) was intravenously administered for 5 to 7 days to 65 patients with complicated urinary tract infections (UTI). Ninety one organisms were isolated from these patients' urine. Among them 66 organisms were eliminated following AZT administration. The elimination rate for Gram negative organisms was 94.7% and that for Gram positive organisms was 33.3%. Thirty one organisms appeared newly by the replacement of organisms. Among them, 12 organisms were E. faecalis. The efficacy rate of AZT in single infection and in mixed infection was 55.8% and 13.7%, respectively. The overall clinical efficacy rate of AZT in the present study was 41.5%. As side effects, skin rash and itching were observed in 3 patients and slight elevations in blood chemistry were observed in 10 patients. The results indicate that AZT is an effective drug for the treatment of patients with complicated UTI, especially those caused by Gram negative organisms.
氨曲南(AZT)(每日2克)静脉注射给药5至7天,用于治疗65例复杂性尿路感染(UTI)患者。从这些患者的尿液中分离出91种微生物。其中,66种微生物在给予氨曲南后被清除。革兰氏阴性菌的清除率为94.7%,革兰氏阳性菌的清除率为33.3%。有31种微生物通过替代原有微生物而新出现。其中,12种微生物为粪肠球菌。氨曲南在单一感染和混合感染中的有效率分别为55.8%和13.7%。本研究中氨曲南的总体临床有效率为41.5%。作为副作用,3例患者出现皮疹和瘙痒,10例患者血液生化指标略有升高。结果表明,氨曲南是治疗复杂性UTI患者的有效药物,尤其是由革兰氏阴性菌引起的患者。